Featured Research

from universities, journals, and other organizations

Costly blood clots more common than expected among cancer patients

Date:
September 20, 2011
Source:
Duke University Medical Center
Summary:
An analysis of more than 30,000 cancer patients has shown that blood clots are a more common complication than doctors may realize, causing additional hospitalizations and driving up the cost of care, according to a new study.

An analysis of more than 30,000 cancer patients has shown that blood clots are a more common complication than doctors may realize, causing additional hospitalizations and driving up the cost of care, according to a study led by a Duke Cancer Institute researcher.

The study, which will be reported Sept. 26 at the 2011 European Multidisciplinary Cancer Congress in Stockholm, found that as many as one in five patients risk developing a blood clot called venous thromboembolism, or VTE, within a year of getting treatment for some types of cancers.

In up to 2 percent of cases the complication is deadly. Clots that form in veins deep in the legs or pelvis can travel to the arteries of the lungs and block blood flow. VTEs are also costly. Cancer patients who develop the clots require medication and hospitalizations that contribute to an average care bill of $110,362, compared to $77,984 for those who do not have VTEs, the study authors reported.

"Direct medical costs of healthcare are significantly greater among cancer patients experiencing a VTE and still do not include caregiver expenses, out of pocket costs and the intangible costs of pain and suffering," said lead author Gary H. Lyman, M.D., M.P.H., a professor of medicine and director of the Comparative Effectiveness and Outcomes Research Program at Duke.

In conducting the study, Lyman and colleagues analyzed 30,552 cancer cases from the InVision™ Data Mart Multiplan/ Integrated Health Care Information Solutions, a large cache of data on more than 17 million U.S. medical patients. The records were of ordinary cancer patients, not participants in clinical trials who tend to be enrolled because they have fewer health issues and therefore develop fewer complications.

The researchers focused on diagnoses of lung, pancreatic, stomach, colon/rectum, bladder and ovarian cancers among patients who began chemotherapy during a four-year period ending in 2008.

Among those in the study group, the risk of developing a VTE within 3.5 months of starting treatment varied widely depending on the type of cancer diagnosed. Bladder cancer carried the lowest risk, at 4.8 percent, and pancreatic cancer had the highest risk, at 11.9 percent. (Colon/rectum 6.1 percent; ovary 6.2 percent; lung 8.5 percent; stomach 8.5 percent)

After a year of treatment, risks nearly doubled across many of the six cancer types, with 9.9 percent of bladder cancer patients and 21.5 percent of pancreatic cancer patients developing clots. (Colon/rectum 11.9 percent; ovary 11.4 percent; lung 14.8 percent; stomach 16.7 percent)

Lyman said scientist don't fully understand why VTEs form during cancer treatment, but have identified certain contributing factors, including blood clotting agents released by tumors, side effects of chemotherapy, and pre-existing health conditions such as obesity and anemia.

He said knowing which patients are at highest risk of developing blood clots could lead to better preventive use of blood thinners. But the preventive use of blood thinners comes with its own risk of potentially dangerous bleeding. A risk score for identifying high risk patients for VTE is based on the type of cancer they have and the other known contributing factors.

"We need more data from randomized control trials in the higher risk populations that would demonstrate a favorable benefit-to-harm ratio from such preventive measures," Lyman said. "Further studies are also needed on the complications of cancer treatment and the associated costs in real-life cancer patients to guide future clinical decisions and more personalized supportive care in patients starting cancer chemotherapy."

In addition to Lyman, study authors included Yanxin Wang; Hongwei Wang; and Alexander T. Cohen.

The study was supported by the pharmaceutical company Sanofi. Lyman received no compensation from Sanofi for his participation.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Costly blood clots more common than expected among cancer patients." ScienceDaily. ScienceDaily, 20 September 2011. <www.sciencedaily.com/releases/2011/09/110920111810.htm>.
Duke University Medical Center. (2011, September 20). Costly blood clots more common than expected among cancer patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/09/110920111810.htm
Duke University Medical Center. "Costly blood clots more common than expected among cancer patients." ScienceDaily. www.sciencedaily.com/releases/2011/09/110920111810.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Newsy (July 23, 2014) An 8-year-old boy helped his younger brother, who has a rare genetic condition that's confined him to a wheelchair, finish a triathlon. Video provided by Newsy
Powered by NewsLook.com
Stone Fruit Listeria Scare Causes Sweeping Recall

Stone Fruit Listeria Scare Causes Sweeping Recall

Newsy (July 22, 2014) The Wawona Packing Company has issued a voluntary recall on the stone fruit it distributes due to a possible Listeria outbreak. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com
CDC Head Concerned About a Post-Antibiotic Era

CDC Head Concerned About a Post-Antibiotic Era

AP (July 22, 2014) Sounding alarms about the growing threat of antibiotic resistance, CDC Director Tom Frieden warned Tuesday if the global community does not confront the problem soon, the world will be living in a devastating post-antibiotic era. (July 22) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins